Replies to post #1538 on Indoor Harvest Corp (INQD)

[Alan Brochstein]

Texas has a horrible program - CBD for epilepsy only initially. The program goes live about the same time GW Pharma could have Epidiolex on the market. Their drug, if approved, would have FDA approval and insurance reimbursement, making the limited Texas program really uncompetitive. In addition, while they operate in the grey, there are lots of providers of CBD from industrial hemp grown overseas or domestically.

TenKay, the company's slide deck calls for pursuing a license in Colorado, but this is not at all possible at present for a public company. This means that the company's due diligence is poor in my view, or they wouldn't make such a claim.

It's a shame that the company was never able to generate sales into the cannabis industry. I thought that they would, but, for whatever reason, they have been slow to prove out acceptance of their technology beyond Canopy Growth. Signing deals with companies that don't have licenses is pretty useless, and now they have given up 60% of the company to another company without a license, Alamo CBD.

I am looking forward to seeing if this is true about the "Vertical Farm Group", or what is now called "The Harvest Group":

http://content.edgar-online.com/edgar_conv_img/2017/01/27/0001640334-17-000188_INQD_EX991IMG17.JPG

The Company is expecting revenue of $3.7mm in the first quarter of 2017...

Very little else has panned out. The former CEO made it seem like the CLARUS program would be a big deal, but he failed miserably on getting it funded. Not too much but penny stock promises from INQD so far...